GSK rectal cancer drug clears tumours in 76% of patients without surgery or chemotherapy
GSK's immunotherapy Jemperli (dostarlimab) showed a 76% complete response rate in rectal cancer patients without surgery or chemotherapy, per interim phase II trial results. 76% of 144 patients had no cancer evidence after treatment, with 68% sustaining response for at least 12 months. No recurrences reported after over two years. US approval granted; data presented at ESMO congress. Serious side effects occurred in 20% of patients.
How this was made
The 30-second read
Why it matters
The interim data suggest a high rate of complete response without surgery, potentially reshaping treatment standards and expanding market opportunity.
Market read
Positive early‑stage data could drive short‑term stock upside and long‑term valuation uplift for GSK's oncology franchise.
What to watch
small patient subset and need for confirmatory Phase III data could temper immediate price moves
Background
GSK's Jemperli (dostarlimab) is an immunotherapy already approved for certain cancers; this trial explores its use as a monotherapy in microsatellite‑instability‑high rectal cancer.
Ticker impact
GSK reported interim Phase II data showing 76% complete response in rectal cancer patients treated with Jemperli.
potential upward pressure as market prices in the favorable efficacy data
First disclosure of high response rates in a niche cancer indication, supporting future sales and possible label expansion.
Market effects
strengthens outlook for oncology biotech and immunotherapy sector
may lift UK pharma stocks and related ADRs
could influence global investors tracking cancer drug pipelines
Counterpoint
caution that long‑term survival data are still pending and regulatory approval may face hurdles
Key entities
- companyGSK
FTSE 100 pharmaceutical company
- drugJemperli
PD‑1 inhibitor immunotherapy
